Treatment for cerebral palsy gait impairment
AssigneeGilrose Pharmaceuticals, LLC
InventorsBruce Roseman, Gilla Kaplan
Life of this patent
Estimating the term…
Abstract
A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
Claims12
A pharmaceutical intervention for a gait or limb impairment resultant from an anti-seizure medicament regimen in a child in need of such intervention, said pharmaceutical intervention comprises a medicament consisting essentially of a therapeutically effective dose of dextro-threo-methylphenidate, wherein the gait or limb impairment is diminished, and the diminishment persists when the dextro-threo-methylphenidate is no longer efficaciously present in the child.
A medicament for treating a gait or limb impairment resultant from an anti-seizure medicament regimen in a subject in need of such treatment, said medicament comprises a therapeutically effective dose of a methylphenidate, whereby the gait or limb impairment is diminished.
Dependencies are inferred from the claim text.